No evidence that ACE2 or TMPRSS2 drive population disparity in COVID risks.

Publication date: Aug 26, 2024

Early in the SARS-CoV2 pandemic, in this journal, Hou et al. (BMC Med 18:216, 2020) interpreted public genotype data, run through functional prediction tools, as suggesting that members of particular human populations carry potentially COVID-risk-increasing variants in genes ACE2 and TMPRSS2 far more often than do members of other populations. Beyond resting on predictions rather than clinical outcomes, and focusing on variants too rare to typify population members even jointly, their claim mistook a well known artifact (that large samples reveal more of a population’s variants than do small samples) as if showing real and congruent population differences for the two genes, rather than lopsided population sampling in their shared source data. We explain that artifact, and contrast it with empirical findings, now ample, that other loci shape personal COVID risks far more significantly than do ACE2 and TMPRSS2-and that variation in ACE2 and TMPRSS2 per se unlikely exacerbates any net population disparity in the effects of such more risk-informative loci.

Open Access PDF

Concepts Keywords
Covid ACE2
Genes ACE2 protein, human
Pandemic Angiotensin-Converting Enzyme 2
Resting Angiotensin-Converting Enzyme 2
COVID
COVID-19
COVID19
Functional prediction
GWAS
Host genetics
Human genes
Humans
Immunity
Infection
Polygenic risk
Population genetics
Population structure
Rare variants
Sample design
Sample size
Sampling
SARS-CoV-2
SARS-CoV2
Serine Endopeptidases
Serine Endopeptidases
TMPRSS2
TMPRSS2 protein, human

Semantics

Type Source Name
disease VO population
disease MESH COVID19
disease IDO host
disease MESH Infection
disease VO Viruses
drug DRUGBANK Coenzyme M
disease VO USA
drug DRUGBANK Ademetionine
drug DRUGBANK Azelaic acid
disease VO frequency
disease VO document
drug DRUGBANK Trestolone
drug DRUGBANK Aspartame
disease VO gene
disease IDO site
disease IDO blood
drug DRUGBANK Methionine
drug DRUGBANK Isoxaflutole
disease VO effective
drug DRUGBANK Angiotensin II
drug DRUGBANK Serine
drug DRUGBANK Methyl pyrrolidone
disease MESH respiratory failure
disease IDO susceptibility
disease MESH critical illness
disease IDO history
drug DRUGBANK Fenamole
drug DRUGBANK Esomeprazole
disease MESH COPD
disease VO vaccine
disease MESH reinfections
disease MESH breakthrough infections
disease VO vaccination
disease IDO contagiousness
disease VO vaccinee
disease MESH influenza
disease VO vaccine effectiveness
disease MESH long COVID

Original Article

(Visited 4 times, 1 visits today)